This Article  • Full text  • PDF  • Original Article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Oncology  • Breast Cancer  • Cardiovascular System  • Statistics and Research Methods  • Women's Health  • Menopause  • Women's Health, Other  • JAMA Classics  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Adverse Effects  • Humanities  • History of Medicine  • Alert me on articles by topic  Social Bookmarking   What's this?

Commentary by Stephen Hulley, MD, MPH; Deborah Grady, MD, MPH

JAMA. 2009;301(23):2493-2495.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

SUMMARY OF THE ORIGINAL ARTICLE

Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women

Stephen Hulley, MD; Deborah Grady, MD; Trudy Bush, PhD; Curt Furberg, MD, PhD; David Herrington, MD; Betty Riggs, MD; Eric Vittinghoff, PhD; for the Heart and Estrogen/progestin Replacement Study (HERS) Research Group

JAMA. 1998;280(7):605-613

Context: Observational studies have found lower rates of coronary heart disease (CHD) in postmenopausal women who take estrogen than in women who do not, but this potential benefit has not been confirmed in clinical trials.

Objective: To determine if estrogen plus progestin therapy alters the risk for CHD events in postmenopausal women with established coronary disease.

Design: Randomized, blinded, placebo-controlled secondary prevention trial.

Setting: Outpatient and community settings at 20 US clinical centers.

Participants: A total of 2763 women with coronary disease, younger than 80 . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?